High-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase.
about
Global phenotypic screening for antimalarialsA long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malariaX-ray structural analysis of Plasmodium falciparum enoyl acyl carrier protein reductase as a pathway toward the optimization of triclosan antimalarial efficacyCharacterization of Trypanosoma brucei dihydroorotate dehydrogenase as a possible drug target; structural, kinetic and RNAi studiesStructural Plasticity of Malaria Dihydroorotate Dehydrogenase Allows Selective Binding of Diverse Chemical ScaffoldsStructure-Guided Lead Optimization of Triazolopyrimidine-Ring Substituents Identifies Potent Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors with Clinical Candidate PotentialFluorine Modulates Species Selectivity in the Triazolopyrimidine Class of Plasmodium falciparum Dihydroorotate Dehydrogenase InhibitorsAntimalarial drug discovery - approaches and progress towards new medicines.High-throughput screening for small-molecule inhibitors of plasmodium falciparum glucose-6-phosphate dehydrogenase 6-phosphogluconolactonaseComparing neural-network scoring functions and the state of the art: applications to common library screeningKinetics and ligand-binding preferences of Mycobacterium tuberculosis thymidylate synthases, ThyA and ThyXAdvancing drug innovation for neglected diseases-criteria for lead progressionThe next opportunity in anti-malaria drug discovery: the liver stageA Teach-Discover-Treat Application of ZincPharmer: An Online Interactive Pharmacophore Modeling and Virtual Screening ToolDisruption of uridine homeostasis links liver pyrimidine metabolism to lipid accumulationTargeting purine and pyrimidine metabolism in human apicomplexan parasitesInhibitors of tubulin assembly identified through screening a compound library.A cell-based high-throughput screen validates the plasmodial surface anion channel as an antimalarial target.Antimalarial drug targets in Plasmodium falciparum predicted by stage-specific metabolic network analysisEvaluation of Diarylureas for Activity Against Plasmodium falciparum.Analysis of flavin oxidation and electron-transfer inhibition in Plasmodium falciparum dihydroorotate dehydrogenase.Discovery of potent and selective inhibitors of Trypanosoma brucei ornithine decarboxylasePlasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy.Insights into Integrated Lead Generation and Target Identification in Malaria and Tuberculosis Drug Discovery.Identification of selective inhibitors of the potassium channel Kv1.1-1.2((3)) by high-throughput virtual screening and automated patch clamp.Antimalarial compounds in Phase II clinical development.Chemical interrogation of the malaria kinome.Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in miceVariation among Plasmodium falciparum strains in their reliance on mitochondrial electron transport chain functionThree-dimensional structures in the design of therapeutics targeting parasitic protozoa: reflections on the past, present and future.The X-ray structure of Plasmodium falciparum dihydroorotate dehydrogenase bound to a potent and selective N-phenylbenzamide inhibitor reveals novel binding-site interactionsStructure of Plasmodium falciparum orotate phosphoribosyltransferase with autologous inhibitory protein-protein interactions.Purine and pyrimidine pathways as targets in Plasmodium falciparum.Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents.Bioisosteric transformations and permutations in the triazolopyrimidine scaffold to identify the minimum pharmacophore required for inhibitory activity against Plasmodium falciparum dihydroorotate dehydrogenaseInnovative lead discovery strategies for tropical diseases.Identification of New Human Malaria Parasite Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors by Pharmacophore and Structure-Based Virtual Screening.Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite Plasmodium falciparum.Transition states of Plasmodium falciparum and human orotate phosphoribosyltransferases.Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice
P2860
Q26824875-233C5216-A8EF-4634-945D-2E4DAD3AF5C0Q27644391-8784C8EC-FD52-47CE-8608-BF45F39AE85BQ27645777-643C913A-E5A9-4ED3-BA9F-F3708AA126E6Q27649971-A32B2535-1981-4C51-A1A6-0FED975A7053Q27656755-F9858FF2-7368-483D-BA69-846ABCDDF967Q27670499-0F8C1302-9C93-443D-B8BF-D18F6D05DE59Q27683656-8DC22A39-A316-4C68-B483-729507F810C7Q27693245-A0426ECC-A5CD-483A-8593-F4EB74F550E4Q28264283-EDFEDFC4-78D0-499F-B77A-E5AEFB3033C7Q28292041-3BE27AC2-BCC8-4F82-8D76-051DD7A13D95Q28472798-595607D1-85F3-42FC-BD19-D9B5E5CA9A68Q28475996-413D5952-7E24-43AA-B33F-BE6A07D31FE4Q28477177-DC377607-D704-4052-8608-10704628A99BQ28547139-B7FDBAE5-0210-4FC2-879E-61FA348B266DQ28593389-98637D56-9E80-4ACA-B942-D458F259A563Q28629739-1DA7CDBC-FC1D-4E28-B4D6-8A06D05B6FE7Q33393885-7EC12E22-F23B-46CD-AC1B-E0D3F95A65A5Q33526535-5A918E27-39E5-4C17-92B5-C051FB2C16FAQ33679330-B978FCA2-AABD-4D8A-B9C5-47976358D501Q33795835-47A81E63-0C17-4645-A115-98B5C4E9621EQ33844680-14861B9F-1E04-45C0-802E-E21D4859385DQ33883491-18520634-AFCF-4899-AC75-AF1671C7AE0DQ33903812-54AE73DC-20C7-465C-AF6B-7843A6C56665Q33919526-4A91727F-F398-4A7F-B549-F124FB15427EQ34219538-8EC97865-BC32-455E-9726-39B0AC72A266Q34456807-1A81F18C-4CBB-4F4B-A66F-45528CBBB6D2Q34541909-D3225E85-9C0A-4835-A709-CEE127BCE22AQ35071496-C5E27E93-E8C5-40E7-B07F-D319142D7493Q35191792-3DA719A3-82C4-4A56-948B-391D72B6FD8CQ35592514-85C71B4A-9E40-4988-8A25-2A97436A8EEDQ35592537-521873D0-67AA-4747-B819-4878A0B4AE23Q35592562-1665FBB2-FBA4-48A7-B078-D4C3500A6F37Q35870244-FCFC31B4-FB19-448A-A58E-2FBABFD23577Q36096646-2AEDAAB8-770E-4808-A171-CF3C767CE314Q36247004-8D1BA3CB-4920-4D62-A4C7-373AE783DEB3Q36642049-DEC11836-9D23-4CD3-840B-EF2DB405EFE6Q36912176-A1B16C75-7F48-4602-AFA4-8AF2AEA864FBQ37057973-AE999007-5EF3-430D-96D5-AFF4DD3996CCQ37159817-8BE246F7-9ED5-474E-BF2E-A57D7EE7D8E6Q37352712-E0D09F0A-5DB4-43E4-B440-C8D74200DB5B
P2860
High-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
High-throughput screening for ...... dihydroorotate dehydrogenase.
@ast
High-throughput screening for ...... dihydroorotate dehydrogenase.
@en
type
label
High-throughput screening for ...... dihydroorotate dehydrogenase.
@ast
High-throughput screening for ...... dihydroorotate dehydrogenase.
@en
prefLabel
High-throughput screening for ...... dihydroorotate dehydrogenase.
@ast
High-throughput screening for ...... dihydroorotate dehydrogenase.
@en
P2093
P2860
P356
P1476
High-throughput screening for ...... dihydroorotate dehydrogenase.
@en
P2093
Carolyn H Michnoff
Jeffrey Baldwin
John White
Margaret A Phillips
Pradipsinh K Rathod
P2860
P304
21847-21853
P356
10.1074/JBC.M501100200
P407
P577
2005-03-28T00:00:00Z